-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABBV-101 in Anaplastic Large Cell Lymphoma (ALCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABBV-101 in Anaplastic Large Cell Lymphoma (ALCL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABBV-101 in Anaplastic Large Cell Lymphoma (ALCL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nadunolimab in Colon Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nadunolimab in Colon Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nadunolimab in Colon Cancer Drug Details: Nadunolimab (CAN-04) is under development...
-
Product Insights
NewBioMark Diagnostics Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our BioMark Diagnostics Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. BioMark Diagnostics Inc (BioMark Diagnostics) is an oncology-focused medical equipment company that owns and develops multiple intellectual properties in the detection and quantitation of metabolites. Its advanced near-to-market diagnostic technologies are designed to improve patient outcomes. Its products include cancer diagnostic tools, Amantadine, cancer management solutions, biomarkers, and others. BioMark Diagnostics offers services such as science of metabolomics research...
-
Product Insights
NewFirst Light Diagnostics Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our First Light Diagnostics Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. First Light Diagnostics Inc (FLD) is a medical device company, that develops and manufactures automated medical diagnostic products for the detection of healthcare associated infections. The company’s product includes multipath analyzer system. Its multipath analyzer system detects resistant and sensitive staphylococcus aureus bacteria, toxins, and viruses for hospital clinical microbiology laboratories. The company manufactures and markets diagnostic products...
-
Product Insights
NewPrometheus Biosciences Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Prometheus Biosciences Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Prometheus Biosciences Inc (Prometheus Biosciences) is the biotech company that discover, develops and commercializes novel therapeutic and companion diagnostic product candidates for inflammatory bowel disease (IBD). The company’s pipeline products include PRA023, an anti-TL1A mAb for the treatment of ulcerative colitis and crohn’s disease; and PR600, PR300, PR1100, PR1800 and PR2100 against inflammatory bowel disease (IBD). It utilizes Prometheus360,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BP-1002 in Cutaneous T-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BP-1002 in Cutaneous T-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BP-1002 in Cutaneous T-Cell Lymphoma Drug Details: BP-1002 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Brentuximab Vedotin in Primary Mediastinal B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Brentuximab Vedotin in Primary Mediastinal B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Brentuximab Vedotin in Primary Mediastinal B-Cell Lymphoma Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Brentuximab Vedotin in Systemic Sclerosis (Scleroderma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Brentuximab Vedotin in Systemic Sclerosis (Scleroderma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Brentuximab Vedotin in Systemic Sclerosis (Scleroderma) Drug Details: Brentuximab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Brentuximab Vedotin in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Brentuximab Vedotin in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Brentuximab Vedotin in Non-Small Cell Lung Cancer Drug...